Add BrightSurf on Google Email

Emerging class of antibiotics to tackle global tuberculosis crisis

A team of scientists at the University of Sydney has discovered how three naturally occurring antibiotic compounds disrupt the ClpC1–ClpP1P2 complex, a vital protein degradation machine in Mycobacterium tuberculosis. This finding uncovers surprising complexity and provides valuable insight into designing more effective anti-TB treatments.

SourceUniversity of Sydney·JournalNature Communications·TypeExperimental study·DateFeb 25, 2026

Study finds no evidence of persistent tick-borne infection in people who link chronic illness to ticks

Researchers studied Norwegians with reported chronic health problems linked to tick bites, finding no objective evidence of persistent infections. The study suggests that physical activity and labour force participation may be more related to symptoms than tick exposure.

SourceNorwegian University of Science and Technology·JournalBMC Infectious Diseases·TypeObservational study·DateFeb 25, 2026

Practice-level metric provides “big-picture” look that may reduce unnecessary antibiotic use in Arkansas Medicaid PCMHs

A study analyzed antibiotic prescribing patterns in Arkansas Medicaid's patient-centered medical home (PCMH) program. The results showed a decrease in pediatric and adult age group claims, with clinics that prescribed the least antibiotics having lower rates in 2021 compared to previous years.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateSep 22, 2025

Common painkillers linked to antibiotic resistance

Research from the University of South Australia finds that ibuprofen and paracetamol drive antibiotic resistance when used individually, but amplifying it when combined. The study also reveals that common bacteria like E. coli become highly resistant to antibiotics and multiple other medications.

SourceUniversity of South Australia·Journalnpj Antimicrobials and Resistance·TypeExperimental study·DateAug 25, 2025

An unexpected bacterial blocker

Scientists at HIRI develop peptide nucleic acid-based compound FUS79, which inhibits Fusobacterium nucleatum growth and exhibits strong activity against five fusobacterial strains without affecting other bacteria. This breakthrough has potential to accelerate research in targeted antibiotics for cancer treatment.

SourceHelmholtz Centre for Infection Research·JournalmBio·TypeExperimental study·DateApr 29, 2025

CARB-X is funding a University of Melbourne research team to develop an oral therapeutic to treat drug-resistant community-acquired bacterial pneumonia

A University of Melbourne research team is developing an oral therapeutic to restore the activity of common antibiotics used to treat community-acquired bacterial pneumonia. The project aims to combat antibiotic-resistant bacteria and reduce healthcare costs, with potential applications in low- and middle-income countries.

Warning over antibiotic-resistant bacteria

A study by Anglia Ruskin University has identified potentially dangerous Pseudomonas bacteria in 21% of wild bird faeces collected from locations near the River Cam. The bacteria, which can be passed on to humans through cross-contamination, were resistant to multiple antibiotics.

SourceAnglia Ruskin University·JournalEcology and Evolution·DateNov 17, 2021